Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cingulate Inc (CING)

Cingulate Inc (CING)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® GlobeNewswire - Thu Jul 2, 7:30AM CDT

KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 GlobeNewswire - Tue Jun 16, 7:00AM CDT

KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Receives Complete Response Letter from FDA for CTx-1301 GlobeNewswire - Tue Jun 2, 7:00AM CDT

No Clinical Safety or Efficacy Concerns Currently Identified  Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 GlobeNewswire - Thu May 14, 7:00AM CDT

KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights GlobeNewswire - Wed Mar 18, 7:00AM CDT

KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules GlobeNewswire - Tue Feb 17, 7:00AM CST

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Thu Nov 13, 2025

Industry Veteran Bryan Downey Named Chief Commercial Officer  NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 GlobeNewswire - Mon Nov 10, 2025

Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control GlobeNewswire - Tue Oct 28, 2025

KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting GlobeNewswire - Thu Oct 23, 2025

KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing...

CING : 5.38 (-8.66%)
CINGW : 0.0232 (+16.00%)

Barchart Exclusives

The Microsoft Stock Outlook Remains Upbeat Despite Layoffs Barchart - 1 hour ago
Microsoft has become a big beneficiary of the AI boom. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.